colorectal cancer
Conditions
Interventions
FOLFIRI plus ramucirumab treatment ramucirumab : administered intravenously at a dose of 8 mg/kg over 60 minutes on day 1. l-leucovorin: administered intravenously at a dose of 200 mg/m2 over 120 mi
Sponsors
Nagoya University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed colorectal adenocarcinoma. 2. Unresectable metastatic disease. 3. Age 20 to 80 years. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 5. Prior oxaliplatin-based chemotherapy. 6. Prior bevacizumab or anti-EGFR containing regimen. 7. Bidimensionally measurable disease. 8. Adequate organ function. 9. The RAS mutation status (wild-type, mutant or not definable) of the patients is known prior to randomization. 10. Written informed consent was obtained.
Exclusion criteria
Exclusion criteria: 1. Previous history of severe drug-induced allergy 2. Brain metastasis 3. Cerebrovascular disease or its symptoms within 1 year. 4. Massive pleural effusion or ascites that required drainage. 5. History of active double cancer. 6. Previous history of thoromboembolitic disease, or necessity for antithrombotic drug. 7. Intestinal bleeding, ileus, bowel obstruction or uncontrolled peptic ulcer. 8. History of gastrointestinal perforation within 1 year. 9. Diathesis of bleeding (history of hemoptysis, including cavitation and/or necrosis in lung metastasis confirmed by imaging), coagulopathy. 10. Severe renal failure or urinary protein (more than 2+). 11. Uncontrolled severe complications (DM, hypertension, diarrhea, et al.). 12. Patient with symptomatic cardiovascular disease or asymptomatic disease but have been treated. 13. Interstitial lung disease or pulmonary fibrosis. 14. Uncontrolled infection. 15. Patient receiving surgical procedure or such as skin-open biopsy, trauma surgery, or other more intensive surgeries within 4 weeks or aspiration biopsy within a week. 16. UGT1A1 gene status of homo type (*28/*28, *6/*6) or double hetero-type genetic polymorphisms *28 or *6 (*1/*28 and *1/*6). 17. Prior irinotecan or ramucirumab containing chemotherapy 18. Pregnant women, possibly pregnant women, wishing to become pregnant, and nursing mothers. 19. Not appropriate for the study at the physician's assessment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival (PFS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (OS), time to treatment failure (TTF), objective response rate (ORR), early tumor shrinkage (ETS), depth of response (DpR), two-dimensional response (2-DR), relative dose intensity (RDI) of irinotecan and ramucirumab, and incidence of adverse events | — |
Countries
Japan
Contacts
Public ContactGoro Nakayama
Nagoya University Graduate School of Medicine Department of Gastroenterological Surgery
Outcome results
None listed